Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Abroad (travel likely)RecruitingPHASE1
Conditions
Relapsed/Refractory AL Amyloidosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Research Site, Beijing, China
Research Site, Beijing, China
Research Site, Beijing, China
Research Site, Changchun, China
Research Site, Guangzhou, China
Research Site, Hangzhou, China
Research Site, Suzhou, China
Research Site, Wenzhou, China
Research Site, Wuhan, China